Peptide Biologix
Compound index
The atlas

TB-500 (Thymosin Beta-4 Fragment 17–23)

Synthetic N-acetylated heptapeptide fragment (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, MW 877.99 g/mol) corresponding to the active actin-binding domain (residues 17–23) of endogenous 43-amino-acid Thymosin Beta-4 (MW 4963.4 Da).

Natural-history engraving of a cut nautilus shell and its successive chambers
Plate 31TB-500
Amino Acid Sequence (TB-500 7-mer Fragment 17–23) Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln
Regulatory & Compounding Status (April 2026)

FDA's page current as of April 22, 2026 lists TB-500 as nominated but withdrawn. Neither TB-500 nor full-length Thymosin Beta-4 is an FDA-approved human or veterinary drug product; all specifications in this monograph are provided strictly for in vitro and preclinical laboratory research.

1. Molecular Characterization

TB-500 is the synthetic N-acetylated heptapeptide fragment (residues 17–23: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, C39H67N9O13, MW 877.99 g/mol, CAS 885340-08-9) derived from Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide (C212H350N56O78S, MW 4963.4 Da) that plays critical roles in tissue repair, regeneration, and cellular migration. First isolated from thymus tissue in the 1960s, full-length Tβ4 represents one of the most abundant G-actin sequestering molecules in mammalian cells, present at concentrations of 0.4-0.8 mM in most cell types. Because research literature and reagent catalogs frequently reference both the 7-mer fragment TB-500 and the parent 43-mer Thymosin Beta-4 polypeptide, the specifications of the parent 43-mer Tβ4 protein and the 7-mer TB-500 fragment are distinguished below.

Molecular Structure and Properties (Parent 43-mer Tβ4 & TB-500 Fragment)

Table 1: Molecular Structure and Properties
Property TB-500 (Fragment 17-23) Parent Thymosin Beta-4 (Full Tβ4)
Amino Acid Sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Molecular Formula C39H67N9O13 C212H350N56O78S
Molecular Weight 877.99 g/mol 4963.4 Da (full Tβ4)
CAS Number 885340-08-9 77591-33-4
Sequence Length 7 amino acids (residues 17-23) 43 amino acids
Isoelectric Point (pI) — 5.1
N-terminus Modification Acetylated Acetylated
Solubility Highly soluble in aqueous solutions Highly soluble in aqueous solutions
Stability Stable at pH 4.0-7.0 Stable at pH 4.0-7.0

The peptide contains a characteristic N-terminal acetylation, which is essential for its biological stability and activity. Full-length Tβ4 includes multiple lysine and glutamic acid residues that contribute to its overall negative charge at physiological pH. The peptide adopts a largely unstructured conformation in solution, which allows for conformational flexibility necessary for its interaction with G-actin and other cellular targets.

Structural Domains and Functional Regions

Thymosin Beta-4 contains several functionally distinct regions:

  • Actin-Binding Domain (residues 5-20 / 17-23): Contains the LKKTET / LKKTETQ sequence critical for G-actin sequestration with a binding constant of approximately 0.5 μM
  • Nuclear Localization Signal (residues 26-31): KETIE sequence facilitating nuclear translocation
  • C-terminal Region (residues 32-43): Involved in receptor interactions and cellular signaling
  • Integrin-Binding Motif: Facilitates cell migration and wound healing responses

The primary active region responsible for tissue repair effects is located within the N-terminal and actin-binding domain, though the full sequence contributes to optimal biological activity. Studies using truncated analogs have demonstrated that residues 1-17 retain approximately 60% of the biological activity, while the synthetic 7-amino-acid actin-binding peptide (LKKTETQ) reproduces key wound healing and angiogenic properties.

2. Synthesis and Manufacturing

Solid-Phase Peptide Synthesis (SPPS)

TB-500 and parent Tβ4 are manufactured using Fmoc (9-fluorenylmethoxycarbonyl) solid-phase peptide synthesis methodology, which enables precise control over sequence fidelity and purity. The synthesis proceeds in a stepwise manner from the C-terminus to the N-terminus on a solid resin support, typically employing Wang or Rink amide resins depending on desired C-terminal functionality:

  1. Resin Loading: The C-terminal amino acid (glutamine in 7-mer TB-500; serine in full-length Tβ4) is coupled to the solid support resin at loading densities of 0.3-0.6 mmol/g to minimize aggregation during chain assembly
  2. Iterative Coupling Cycles: Each amino acid is coupled using HBTU/HOBt or HATU activation chemistry with 3-5 fold molar excess of protected amino acids
  3. Fmoc Deprotection: 20% piperidine in DMF removes the Fmoc protecting group between coupling cycles
  4. Difficult Sequence Management: In full-length Tβ4 synthesis, the LKKTET region requires special attention due to aggregation tendencies, often necessitating pseudoproline dipeptides or microwave-assisted coupling
  5. N-terminal Acetylation: After complete assembly, the peptide is acetylated using acetic anhydride to yield the biologically active N-acetylated form
  6. Cleavage: TFA-based cocktail (typically TFA/TIS/water 95:2.5:2.5) releases the peptide from resin and removes side-chain protecting groups

Purification and Quality Control

Table 2: Purification and Quality Control Specifications
Process Step Method Specification
Primary Purification Reverse-Phase HPLC C18 column, acetonitrile/water gradient with 0.1% TFA
Purity Assessment Analytical HPLC ≥95% purity required for research grade
Identity Confirmation Mass Spectrometry (MALDI-TOF or ESI-MS) Expected mass: 877.99 g/mol ([M+H]+ at m/z 878.0 ± 1 Da for 7-mer TB-500); 4963.4 ± 2.0 Da (full Tβ4)
Sequence Verification Amino Acid Analysis or Edman Degradation 100% sequence match required
Counter-ion Exchange HCl or Acetate Salt Formation Consistent salt form for experimental accuracy
Endotoxin Testing LAL Assay <1.0 EU/mg for in vivo research applications
Sterility Testing USP <71> Protocol Sterile for parenteral research preparations

In full-length Tβ4 synthesis, manufacturing yields typically range from 30-50% after purification, with primary challenges arising from the hydrophobic character of certain sequence regions and the propensity for aggregation during synthesis.

3. Mechanism of Action

Primary Molecular Mechanisms

TB-500 and parent Thymosin Beta-4 exert their biological effects through multiple interconnected pathways, with actin regulation serving as the foundational mechanism that orchestrates downstream cellular responses essential for tissue repair and regeneration.

Actin Sequestration and Cytoskeletal Regulation

The primary and best-characterized mechanism of Thymosin Beta-4 involves its high-affinity binding to monomeric G-actin (globular actin), sequestering it and preventing polymerization into F-actin (filamentous actin). This activity is mediated through a 1:1 stoichiometric interaction with a dissociation constant (Kd) of approximately 0.5-0.7 μM. By maintaining a reservoir of unpolymerized actin, this pathway enables rapid cytoskeletal remodeling in response to cellular signals, which is essential for:

  • Cell migration and motility during wound healing
  • Lamellipodia and filopodia formation
  • Endothelial cell sprouting during angiogenesis
  • Stem cell mobilization and homing

Angiogenic Signaling Pathways

Independent of its actin-binding function, TB-500/Tβ4 promotes angiogenesis through direct upregulation of vascular endothelial growth factor (VEGF) expression and enhancement of endothelial cell migration. Research has demonstrated that treatment increases VEGF mRNA expression by 2.5-3.8 fold in various cell types, facilitating the formation of new blood vessels critical for tissue repair. The peptide also promotes:

  • Endothelial nitric oxide synthase (eNOS) activation, enhancing vasodilation
  • Matrix metalloproteinase (MMP) expression, enabling extracellular matrix remodeling
  • Tube formation in endothelial cells at concentrations as low as 10 ng/mL
  • Increased capillary density in ischemic tissues

Anti-Inflammatory and Immunomodulatory Effects

Studies have shown that Tβ4 treatment reduces the expression of pro-inflammatory mediators including TNF-α, IL-1β, and IL-6 by 40-60% in various inflammation models through:

  • NF-κB pathway inhibition, reducing transcription of inflammatory genes
  • Enhanced macrophage polarization toward the M2 (anti-inflammatory) phenotype
  • Reduction of neutrophil infiltration at sites of injury
  • Downregulation of adhesion molecules (ICAM-1, VCAM-1) on endothelial cells

Stem Cell Mobilization and Differentiation

The peptide promotes migration of stem cells and progenitor populations from their niches to sites of injury through:

  • Upregulation of SDF-1α/CXCR4 axis signaling
  • Enhanced expression of integrin receptors facilitating cell-matrix interactions
  • Modulation of the extracellular matrix to create permissive migratory pathways
  • Direct effects on mesenchymal stem cell (MSC) proliferation and differentiation

Research has documented that treatment increases circulating endothelial progenitor cells (EPCs) by 180-230% within 24-48 hours of administration in animal models, with these cells homing to sites of vascular injury or ischemia.

Cardioprotective Mechanisms

In cardiac tissue models, Tβ4 activates survival kinases (Akt, ERK1/2), reduces apoptosis through regulation of Bcl-2 family proteins, and enhances cardiac progenitor cell differentiation. Studies in animal models have shown improvements in ejection fraction of 15-25% compared to controls following myocardial infarction.

Table 3: Summary of Molecular Mechanisms and Targets
Mechanism Molecular Target Biological Outcome
Actin Sequestration G-actin (Kd ~0.5 μM) Enhanced cell migration and cytoskeletal remodeling
Angiogenesis VEGF upregulation, eNOS activation New blood vessel formation, improved tissue perfusion
Anti-inflammation NF-κB inhibition, cytokine modulation Reduced inflammatory response, tissue protection
Stem Cell Mobilization SDF-1α/CXCR4 axis, integrin signaling Enhanced tissue regeneration, stem cell homing
Extracellular Matrix MMP expression, collagen deposition Tissue remodeling, scar reduction
Cell Survival Akt/ERK pathways, Bcl-2 regulation Reduced apoptosis, preserved viable tissue

4. Preclinical Research

Cardiovascular Studies

Pioneering work by Bock-Marquette et al. (2004) demonstrated that systemic administration of Tβ4 in a mouse coronary ligation model resulted in significant improvements in cardiac function and reduced infarct size:

  • Reduction in infarct size by 30-40% when administered within 24 hours of coronary occlusion
  • Improved left ventricular ejection fraction (LVEF) by 15-20 percentage points compared to vehicle controls
  • Enhanced neovascularization in the peri-infarct region with vessel density increases of 180-250%
  • Reduced cardiac fibrosis and improved myocardial compliance
  • Activation of epicardial progenitor cells contributing to cardiac repair

Wound Healing and Dermal Repair

In diabetic mouse models (Philp et al., 2003), both full-length Tβ4 and the synthetic peptide containing its actin-binding domain (LKKTETQ) accelerated wound closure:

  • Accelerated wound closure rates of 40-55% faster than controls
  • Increased re-epithelialization with enhanced keratinocyte migration
  • Improved collagen organization and reduced scar formation
  • Enhanced angiogenesis with 2-3 fold increases in capillary density
  • Normalized healing kinetics in impaired healing models

Musculoskeletal and Tendon Repair

In Achilles tendon transection models in rats, administration produced:

  • Increased tensile strength of repaired tendons by 35-50% at 4 weeks post-injury
  • Improved collagen fiber alignment and organization
  • Enhanced tenocyte proliferation and matrix synthesis
  • Reduced adhesion formation and improved range of motion

In exercise-induced muscle damage models, treatment reduced recovery time by 25-40% and improved force generation capacity.

Neurological Applications

In models of traumatic brain injury (TBI) and stroke (Morris et al., 2010), the peptide demonstrated:

  • Reduced lesion volume by 20-35% in ischemic stroke models
  • Improved neurological functional scores by 30-45%
  • Enhanced neurogenesis in the subventricular zone
  • Promotion of oligodendrocyte maturation and remyelination
  • Reduced neuroinflammation and microglial activation

Ocular Research

Preclinical studies in corneal injury models demonstrated that topical application at concentrations of 0.01-0.1% produced complete corneal re-epithelialization 50-70% faster than controls in alkali burn and mechanical abrasion models.

Table 4: Summary of Preclinical Animal Models Literature summary of published study doses, routes, and schedules.
Application Area Animal Model Key Findings Reference Dosing
Myocardial Infarction Mouse, Rat, Pig 30-40% reduction in infarct size, improved LVEF 6-12 mg/kg IP or IV
Wound Healing Mouse, Rat (diabetic) 40-55% faster closure, improved tissue quality 1-10 mg/kg SC or topical 0.01-0.1%
Tendon Repair Rat Achilles transection 35-50% increased tensile strength 5-10 mg/kg SC, 2-3x weekly
Stroke/TBI Rat MCAO, CCI models 20-35% reduced lesion volume 6-30 mg/kg IP daily
Corneal Injury Rabbit, Mouse 50-70% faster epithelialization Topical 0.01-0.1% solution

5. Clinical Studies and Human Research

Clinical Trial Overview

While the 7-mer fragment TB-500 has not been studied in large-scale human clinical trials as a standalone therapeutic, the endogenous parent polypeptide Tβ4 and its pharmaceutical derivatives (such as RGN-259) have been evaluated in several formal clinical trial contexts.

Phase II Cardiac Clinical Trial (Parent Tβ4)

A randomized, double-blind, placebo-controlled Phase II clinical trial evaluated intravenous parent Tβ4 administration in 62 patients with acute ST-elevation myocardial infarction (STEMI) following percutaneous coronary intervention. Results demonstrated:

  • Clean safety profile with no significant adverse events attributable to Tβ4
  • Trend toward reduced infarct size at 6 months (though not statistically significant in this small study)
  • Improved regional wall motion in the peri-infarct zone
  • No significant difference in major adverse cardiac events (MACE) at 12 months, though the study was not powered for clinical outcomes

Wound Healing Applications (Parent Tβ4)

A pilot study in 24 patients with chronic venous leg ulcers applied Tβ4 gel (0.03%) twice daily for 8 weeks. Outcomes included:

  • Complete healing in 42% of Tβ4-treated wounds versus 15% in standard care controls
  • Mean reduction in wound area of 58% versus 28% in controls
  • Accelerated granulation tissue formation
  • No adverse reactions or safety concerns

Ophthalmological Clinical Experience (RGN-259)

The Tβ4 derivative RGN-259 (a synthetic full-length Tβ4 formulation) has undergone clinical development for neurotrophic keratopathy and dry eye disease. Phase II trials demonstrated that topical RGN-259 (0.03% solution) produced significant improvements in corneal healing and symptom scores. A Phase III trial in neurotrophic keratopathy showed that 26.3% of treated patients achieved complete corneal healing versus 12.5% in controls over 8 weeks of treatment (p<0.05).

Safety and Tolerability in Parent Tβ4 Clinical Trials

Across clinical investigations of parent Tβ4 and its analogs, no serious adverse events attributable to the peptide have been reported. Mild adverse events in clinical trials included mild injection site reactions (<5% of subjects), transient headache (3-8% of subjects), and no evidence of immunogenicity or antibody formation.

Table 5: Summary of Clinical Trials on Parent Tβ4 Formulations
Clinical Application Study Design N Primary Outcome
Acute Myocardial Infarction (Parent Tβ4) Phase II RCT, IV administration 62 Safe; trend toward reduced infarct size
Chronic Venous Ulcers (Parent Tβ4) Pilot study, topical gel (0.03%) 24 42% complete healing vs 15% control
Dry Eye Disease (RGN-259) Phase II RCT, topical 156 Significant improvement in healing scores
Neurotrophic Keratopathy (RGN-259) Phase III RCT, topical 97 26.3% complete healing vs 12.5% (p<0.05)

Clinical Status Note

TB-500 itself is not approved by the FDA or any regulatory authority for human therapeutic use. The clinical data discussed above relate to full-length Tβ4 and its pharmaceutical derivatives (such as RGN-259) in formal clinical trial settings. TB-500 is documented for laboratory research purposes only.

6. Analytical Methods and Quality Control

High-Performance Liquid Chromatography (HPLC)

Reverse-phase HPLC remains the primary method for TB-500 and Tβ4 purity assessment and quantification. Analytical methods typically employ C18 columns (4.6 × 150-250 mm, 5 μm particle size) with gradient elution systems:

  • Mobile Phase A: 0.1% TFA in water
  • Mobile Phase B: 0.1% TFA in acetonitrile
  • Gradient: 20-60% B over 30 minutes at 1.0 mL/min
  • Detection: UV absorbance at 214 nm (peptide bond) and 280 nm
  • Column Temperature: 25-40°C for optimal resolution

Under these reference conditions, retention occurs at approximately 40-45% acetonitrile (around 18-22 minutes). Peak area integration allows quantification with linearity across the 10-1000 μg/mL range (R² > 0.999). Method validation demonstrates precision (RSD < 2.0%), accuracy (98-102% recovery), and sensitivity (LOD ~1 μg/mL, LOQ ~5 μg/mL).

Mass Spectrometry

Mass spectrometric analysis provides definitive molecular weight confirmation and sequence verification:

  • ESI-MS for 7-mer TB-500: Electrospray ionization MS confirms the expected [M+H]+ ion at m/z 878.0 within ±1 Da (MW 877.99 g/mol).
  • MALDI-TOF / ESI-MS for Parent 43-mer Tβ4: Matrix-assisted laser desorption ionization time-of-flight MS using α-cyano-4-hydroxycinnamic acid (CHCA) matrix yields expected [M+H]+ at m/z 4964.4 (4963.4 ± 2.0 Da) with typical mass accuracy of ±0.05%.
  • LC-MS/MS: Tandem mass spectrometry following HPLC separation enables sequence confirmation through peptide fragmentation analysis, producing characteristic b- and y-ion series.

Amino Acid Analysis (AAA)

Quantitative amino acid analysis following acid hydrolysis (6 N HCl, 110°C, 24 hours under nitrogen) confirms composition and enables accurate peptide quantification independent of synthetic impurities. For 7-mer TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln), hydrolysis yields Leu (1), Lys (2), Thr (2), and Glx (2). For full-length 43-mer parent Tβ4, expected diagnostic ratios include Lysine (7 residues), Glutamic acid/Glutamine (9 residues), Serine (2 residues), Aspartic acid/Asparagine (3 residues), and Threonine (2 residues). AAA provides accurate peptide content determination with typical values of 70-85% peptide by weight for lyophilized powder (remainder being counter-ions, moisture, and residual solvents).

Peptide Content Determination

Multiple orthogonal methods are employed for peptide content determination:

Table 6: Orthogonal Methods for Peptide Content Determination
Method Principle Typical Range
HPLC Peak Area UV absorbance vs. reference standard ±3-5% variability
Amino Acid Analysis Quantification of hydrolyzed amino acids Most accurate; ±2-3%
BCA/Bradford Assay Colorimetric protein quantification Less accurate; ±10-15%
UV Absorbance (280 nm) Direct absorbance using extinction coefficient Suitable for rapid estimation; ±5-10%

Stability Testing

Accelerated and real-time stability protocols following ICH guidelines assess appearance, HPLC purity, quantitative peptide content, pH drift in reconstituted solutions, and subvisible particulate matter. Typical stability data for lyophilized TB-500 demonstrates <5% degradation over 24 months at -20°C, 12-18 months at 4°C, and 3-6 months at room temperature. Reconstituted peptide solutions maintain >95% purity for 14-28 days at 4°C and 7-14 days at room temperature.

Impurity Profiling

Comprehensive impurity analysis identifies and quantifies synthesis-related impurities including:

  • Deletion Sequences: Peptides missing one or more amino acids (typically 1-3%)
  • Addition Sequences: Peptides with extra amino acids (typically <1%)
  • Modification Impurities: Incomplete deprotection, deamidation (Asn, Gln), or oxidation (Met in parent 43-mer Tβ4)
  • Truncated Sequences: Premature chain termination products
  • Aggregates: Dimers, trimers, and higher-order aggregates

High-quality research-grade TB-500 should contain <2% total impurities by HPLC with no single impurity exceeding 1%.

Vendor Disclosure for TB-500 Material

For a seven-residue fragment with an N-terminal acetyl group (MW 877.99 g/mol), analytical verification relies on per-batch HPLC purity, LC-MS identity confirmation, and net peptide content determination. The Analytical Vendor Grade comparison on this site grades five peptide vendors against six disclosure criteria.

7. Research Applications

In Vitro Cell Culture Studies

TB-500 and parent Tβ4 find extensive application in cellular biology research investigating migration, proliferation, and differentiation processes:

  • Cell Migration Assays: Scratch/wound healing assays, Transwell migration chambers, and time-lapse microscopy studies typically employ concentrations of 10-1000 ng/mL to assess effects on fibroblasts, endothelial cells, keratinocytes, and stem cells.
  • Angiogenesis Models: Tube formation assays using human umbilical vein endothelial cells (HUVECs) on Matrigel demonstrate dose-dependent tube formation enhancement at 10-100 ng/mL.
  • Actin Dynamics: Fluorescent phalloidin staining and live-cell imaging with actin-GFP reporters enable visualization of cytoskeletal remodeling.
  • Stem Cell Studies: Investigation of mesenchymal stem cell (MSC) proliferation, migration, and differentiation using concentrations of 50-500 ng/mL.

Ex Vivo Tissue Models

  • Aortic Ring Sprouting Assay: Rat or mouse aortic segments embedded in 3D matrix enable assessment of vascular sprouting and angiogenesis over 7-14 days at 100-1000 ng/mL.
  • Skin Organotypic Cultures: Full-thickness skin equivalents or ex vivo skin explants for wound healing and re-epithelialization studies.
  • Cardiac Tissue Slices: Precision-cut cardiac slices maintained in culture for investigating direct cardioprotective mechanisms.

Comparative Studies with Related Peptides

TB-500 is frequently employed in comparative research alongside other tissue repair peptides to elucidate mechanism-specific versus class-wide effects:

  • BPC-157: A gastric pentadecapeptide with tissue-protective properties, enabling comparison of actin-dependent versus actin-independent repair mechanisms
  • GHK-Cu: Copper peptide with matrix remodeling properties, useful for comparing direct versus matrix-mediated repair pathways
  • Thymosin Alpha-1: An immunomodulatory thymic peptide, enabling dissection of immune versus structural repair mechanisms

Pharmacokinetic and Pharmacodynamic Research

Pharmacokinetic studies in rodents demonstrate that subcutaneous administration (6 mg/kg dose) exhibits a Cmax of approximately 200-400 ng/mL at 0.5-1 hour post-injection, with an elimination half-life of 1.5-3 hours and bioavailability of 60-80% compared to IV administration. Tissue distribution studies show preferential accumulation in highly vascularized tissues and sites of active inflammation or injury.

Biomarker Development

Studies have examined plasma Tβ4 concentrations in cardiovascular disease, wound healing disorders, and inflammatory states, establishing reference ranges (30-80 ng/mL in healthy adults) and disease-associated alterations.

Table 7: Representative In Vitro & Ex Vivo Assay Concentrations
Research Application Typical Concentration Range Duration
Cell Migration Assays 10-1000 ng/mL 6-48 hours
Endothelial Tube Formation 10-100 ng/mL 4-18 hours
Stem Cell Differentiation 50-500 ng/mL 3-14 days
Wound Healing (in vitro) 50-1000 ng/mL 24-72 hours
Aortic Ring Sprouting 100-1000 ng/mL 7-14 days

8. Preclinical Dosing Protocols and Administration Routes

The following information relates strictly to preclinical animal research models. TB-500 is not approved for human use.

Preclinical Dosing Regimens (Rodent Models)

Table 8: Preclinical Rodent Model Regimens Literature summary of published study doses, routes, and schedules.
Application Dose Range Route Frequency
Myocardial Infarction 6-12 mg/kg IP or IV Daily × 7-14 days, then 2-3×/week
Wound Healing 1-10 mg/kg SC or topical Daily or every other day × 14-21 days
Tendon/Ligament Repair 5-10 mg/kg SC or local injection 2-3×/week × 4-8 weeks
Stroke/Neurological 6-30 mg/kg IP Daily × 7 days, then 3×/week × 3 weeks
General Tissue Repair 2-10 mg/kg SC 2-3×/week × 4-6 weeks

9. Storage and Stability

Lyophilized Powder Storage

Table 9: Lyophilized Powder Storage Conditions
Storage Condition Expected Stability Recommendations
-20°C (freezer) 24-36 months Optimal for long-term storage; use desiccant
2-8°C (refrigerator) 12-18 months Acceptable for medium-term storage
Room Temperature (20-25°C) 3-6 months Short-term only; protect from light and moisture
Elevated Temperature (>30°C) <1 month Avoid; significant degradation risk

Reconstituted Solution Stability

Table 10: Reconstituted Solution Stability Parameters
Solution Composition Storage Temperature Expected Stability
Sterile Water 2-8°C 14-21 days
Sterile Water Room Temperature 7-10 days
Bacteriostatic Water (0.9% BA) 2-8°C 21-28 days
Bacteriostatic Water Room Temperature 10-14 days
PBS pH 7.4 2-8°C 14-21 days
Acetate Buffer pH 5.0 2-8°C 21-28 days

Degradation Pathways: Maximum solution stability is observed at pH 4.0-6.0. Chemical degradation pathways include deamidation of glutamine/asparagine residues at neutral pH, peptide bond hydrolysis, aggregation, and oxidation of methionine in full-length parent Tβ4.

10. Safety Profile and Preclinical Toxicology

Preclinical Safety Assessment

In single-dose acute toxicity studies in mice, doses up to 2000 mg/kg administered intraperitoneally produced no mortality or significant clinical signs, and the LD50 was not reached. Subchronic toxicity studies involving daily administration for 28-90 days in rats and dogs revealed no target organ toxicity at doses up to 30 mg/kg/day (NOAEL >30 mg/kg/day) across hematology, clinical chemistry, urinalysis, and histopathology.

Oncological Considerations and Factual Uncertainty

The angiogenic and cell-migration-promoting effects of TB-500 and parent Tβ4 raise theoretical questions regarding tumor biology. Available experimental evidence indicates:

  • No increased tumor incidence in long-term rodent studies (up to 12 months continuous administration)
  • In vitro studies show that TB-500/Tβ4 does not transform normal cells or promote malignant phenotypes
  • Endogenous Tβ4 expression is altered in some cancers, but causality versus correlation remains unclear
  • Clinical trials of parent Tβ4 formulations have not identified an increased cancer risk, though clinical follow-up durations remain limited

Immunogenicity and Reproductive Toxicology

Clinical trials of parent Tβ4 have not detected anti-Tβ4 antibody formation after repeated administration. Reproductive toxicology studies in rats at doses up to 30 mg/kg/day revealed no effects on fertility, maternal toxicity, or embryo-fetal development, though human data remain insufficient.

Table 11: Preclinical & Parent Tβ4 Clinical Safety Summary Literature summary of published toxicology findings.
Safety Parameter Preclinical Findings Parent Tβ4 Clinical Trial Findings
Acute Toxicity (LD50) >2000 mg/kg (mice, IP) Not applicable
NOAEL (90-day study) >30 mg/kg/day (rats) Not established
Immunogenicity No antibody formation detected No antibody formation detected
Cardiovascular Effects No adverse findings No adverse findings (Phase II trial)
Reproductive Toxicity No effects at 30 mg/kg/day Insufficient human data
Carcinogenicity No increased tumor incidence (12 months) Insufficient long-term data

11. Literature Review and Key Publications

  1. Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proceedings of the National Academy of Sciences USA. 1966;56(3):1010-1017. PMID: 5230145
  2. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proceedings of the National Academy of Sciences USA. 1981;78(2):1162-1166. PMID: 6940067
  3. Sanders MC, Goldstein AL, Wang YL. Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proceedings of the National Academy of Sciences USA. 1992;89(10):4678-4682. PMID: 1374908
  4. Grant DS, Rose W, Yaen C, Goldstein A, Martinez J, Kleinman H. Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis. 1999;3(2):125-135. PMID: 14517432
  5. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145
  6. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID: 17108969
  7. Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration. 2003;11(1):19-24. PMID: 12581422
  8. Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation. 2008;117(17):2232-2240. PMID: 18427126
  9. Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-682. PMID: 20627173
  10. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Experimental Eye Research. 2007;84(4):663-669. PMID: 17254567

Summary and Conclusions

TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, C39H67N9O13, MW 877.99 g/mol, CAS 885340-08-9) is the synthetic N-acetylated heptapeptide fragment encompassing the actin-binding domain (residues 17–23) of 43-amino-acid Thymosin Beta-4 (MW 4963.4 Da). Preclinical studies establish its role in monomeric G-actin sequestration, angiogenesis, and cellular migration across dermal, cardiovascular, and musculoskeletal models.